Skip to content

Study · Animal study (in vivo) · guinea pig · 2000

3 results

Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.

Bhardwaj R, Hadley ME, Dorr RT, Dvorakova K, Brooks C, Blanchard J

Pharmaceutical research1 May 2000Cited by 6 (Europe PMC)

PMID10888312 (opens in a new tab)DOI10.1023/a:1007525117894 (opens in a new tab)PepBankPUB-10888312
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In guinea pigs given subcutaneous implants with 4 mg MT-I, skin darkening lasted up to three months, with luminance values falling from 0 to -4.82.

    In plain wordsIn guinea pigs, MT-I implants darkened the skin for up to three months.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseSkin darkening (luminance)
    Study

    guinea pign: not reported in source

    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    4 mg · subcutaneous implantAs given in this study (guinea pig).

    Measurements

    Luminance change
    −4.82 luminance value
    up to three months

    Source sentences

    Summary
    The reflectance readings demonstrated a prolonged skin darkening for up to three months as evidenced by the decrease in the luminance values from 0 to -4.82.
    1 context sentence
    Summary · context
    The effect of MT-I on skin pigmentation was measured using a Chroma meter (reflectometer) after subcutaneous administration of implants containing 4 mg MT-I to guinea pigs.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In guinea pigs given subcutaneous implants with 4 mg MT-I, eumelanin levels rose 2.5-fold after one month, and the increase lasted 3 months.

    In plain wordsIn guinea pigs, MT-I implants raised skin eumelanin pigment, and the rise lasted three months.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseSkin eumelanin level
    Study

    guinea pign: not reported in source

    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    4 mg · subcutaneous implantAs given in this study (guinea pig).

    Measurements

    Eumelanin increase
    2.5 fold
    after one month

    Source sentences

    Summary
    A 2.5-fold increase in eumelanin levels was observed after one month and the increased pigmentation lasted for 3 months.
    1 context sentence
    Summary · context
    The objective of this study was to evaluate in vitro and in vivo the melanogenic activity of one-month duration Melanotan-I (MT-I) implants prepared using poly (D,L lactide-co-glycolide) polymer.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 03LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    In a frog skin bioassay, MT-I released from implants for 24 hours showed 100% melanotropic activity compared with a fresh MT-I standard.

    In plain wordsIn lab tests on frog skin, MT-I released from implants was as active as freshly made MT-I.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeMelanotropic activity of MT-I released in vitro from implants
    Study

    frogn: not reported in source

    Comparator
    freshly prepared MT-I standard
    Outcome group
    Pigmentation · Skin and wound

    Measurements

    Melanotropic activity
    100%
    released MT-I vs fresh standard, 24 h

    Source sentences

    Summary
    The MT-I released in vitro from implants after 24 hours exhibited 100% melanotropic activity in frog skins compared to an identical concentration of a freshly prepared MT-I standard.
    1 context sentence
    Summary · context
    The objective of this study was to evaluate in vitro and in vivo the melanogenic activity of one-month duration Melanotan-I (MT-I) implants prepared using poly (D,L lactide-co-glycolide) polymer.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.